NCT00677313View on ClinicalTrials.gov

An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Lipodystrophy
Interventions
DRUG

metreleptin

metreleptin injection

Trial Locations (5)

89502

Local Institution, Reno

Unknown

Research Site, Santa Barbara

Research Site, Chicago

Research Site, Ann Arbor

Research Site, Greenville

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00677313 - An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy | Biotech Hunter | Biotech Hunter